161 related articles for article (PubMed ID: 2013808)
21. Extranodal malignant lymphoma: detection with FDG PET versus CT.
Moog F; Bangerter M; Diederichs CG; Guhlmann A; Merkle E; Frickhofen N; Reske SN
Radiology; 1998 Feb; 206(2):475-81. PubMed ID: 9457202
[TBL] [Abstract][Full Text] [Related]
22. [Correlation of ¹⁸F-FDG uptake with tumor-proliferating antigen Ki-67 expression in aggressive lymphoma].
Liang Y; Wu N; Fang Y; Huang WT; Zhang H; Zheng R; Zhang WJ; Liu Y; Li XM
Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):356-60. PubMed ID: 24054012
[TBL] [Abstract][Full Text] [Related]
23. [Role of 18Fluorine-deoxyglucose (FDG) positron emission tomography in the management of lymphomas].
Massardo V T; Canessa G J; Jofré M MJ; González E P; Humeres A P; Sierralta G P
Rev Med Chil; 2006 Jul; 134(7):910-9. PubMed ID: 17130976
[TBL] [Abstract][Full Text] [Related]
24. [18F-FDG uptake of lymphoma lesions of various histological subtypes].
Ma LF; Fan W
Ai Zheng; 2009 Apr; 28(4):425-30. PubMed ID: 19622306
[TBL] [Abstract][Full Text] [Related]
25. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in the treatment of Hodgkin's disease and malignant non-Hodgkin's lymphoma].
Bourguet P;
Bull Cancer; 2003 Feb; 90 Spec No():S88-95. PubMed ID: 12739340
[No Abstract] [Full Text] [Related]
26. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography.
Rosenfeld SS; Hoffman JM; Coleman RE; Glantz MJ; Hanson MW; Schold SC
J Nucl Med; 1992 Apr; 33(4):532-6. PubMed ID: 1552337
[TBL] [Abstract][Full Text] [Related]
27. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
[TBL] [Abstract][Full Text] [Related]
28. [Lymphography in malignant lymphomas (report of 200 cases)].
Blaudow K
Radiobiol Radiother (Berl); 1970; 11(5):559-79. PubMed ID: 4928133
[No Abstract] [Full Text] [Related]
29. The use of PET-18FDG imaging in the clinical evaluation of head and neck lymphoma.
Walsh RM; Wong WL; Chevretton EB; Beaney RP
Clin Oncol (R Coll Radiol); 1996; 8(1):51-4. PubMed ID: 8688363
[TBL] [Abstract][Full Text] [Related]
30. Primary muscle lymphoma: clinical and imaging findings.
Lee VS; Martinez S; Coleman RE
Radiology; 1997 Apr; 203(1):237-44. PubMed ID: 9122401
[TBL] [Abstract][Full Text] [Related]
31. FDG-PET for the evaluation of tumor viability after anticancer therapy.
Okada J; Oonishi H; Yoshikawa K; Imaseki K; Uno K; Itami J; Arimizu N
Ann Nucl Med; 1994 May; 8(2):109-13. PubMed ID: 8074956
[TBL] [Abstract][Full Text] [Related]
32. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study.
Del Puig Cózar-Santiago M; García-Garzón JR; Moragas-Freixa M; Soler-Peter M; Bassa Massanas P; Sánchez-Delgado M; Sanchez-Jurado R; Aguilar-Barrios JE; Sanz-Llorens R; Ferrer-Rebolleda J
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373
[TBL] [Abstract][Full Text] [Related]
33. [18F]fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin.
Minn H; Leskinen-Kallio S; Lindholm P; Bergman J; Ruotsalainen U; Teräs M; Haaparanta M
J Comput Assist Tomogr; 1993; 17(1):115-23. PubMed ID: 8419418
[TBL] [Abstract][Full Text] [Related]
34. Spontaneous regression of follicular, mantle cell, and diffuse large B-cell non-Hodgkin's lymphomas detected by FDG-PET imaging.
Kumar R; Bhargava P; Zhuang H; Yu JQ; Schuster SJ; Alavi A
Clin Nucl Med; 2004 Nov; 29(11):685-8. PubMed ID: 15483478
[TBL] [Abstract][Full Text] [Related]
35. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
Buchmann I; Reinhardt M; Elsner K; Bunjes D; Altehoefer C; Finke J; Moser E; Glatting G; Kotzerke J; Guhlmann CA; Schirrmeister H; Reske SN
Cancer; 2001 Mar; 91(5):889-99. PubMed ID: 11251940
[TBL] [Abstract][Full Text] [Related]
36. Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography.
Khandani AH; Dunphy CH; Meteesatien P; Dufault DL; Ivanovic M; Shea TC
Nucl Med Commun; 2009 Aug; 30(8):594-601. PubMed ID: 19536037
[TBL] [Abstract][Full Text] [Related]
37. [Role of 18F-FDG PET in tumor grading and evaluating effectiveness of therapy in malignant lymphomas].
Tlostanova MS; Tiutin LA; Ryzhkova DV; Il'in NV; Ivanova EI; Vinogradova IuN; Ivanova AA; Savchenko ON
Vopr Onkol; 2008; 54(4):475-9. PubMed ID: 18942403
[TBL] [Abstract][Full Text] [Related]
38. The role of PET imaging in lymphoma.
Burton C; Ell P; Linch D
Br J Haematol; 2004 Sep; 126(6):772-84. PubMed ID: 15352980
[TBL] [Abstract][Full Text] [Related]
39. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer.
Lindholm P; Leskinen-Kallio S; Minn H; Bergman J; Haaparanta M; Lehikoinen P; Någren K; Ruotsalainen U; Teräs M; Joensuu H
J Nucl Med; 1993 Oct; 34(10):1711-6. PubMed ID: 8410288
[TBL] [Abstract][Full Text] [Related]
40. [FDG-PET on the day after first chemotherapy in malignant lymphoma].
Yamane T; Daimaru O; Itoh S; Nagata T; Yoshiya K; Itoh S; Uchida H; Shinai T; Imai T; Ohishi H
Nihon Igaku Hoshasen Gakkai Zasshi; 2002 Dec; 62(14):839-42. PubMed ID: 12607955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
